Unlike classical anti-platelet drugs that primarily target platelet aggregation, 1,8-cineole specifically disrupts the P-selectin-PSGL-1 axis, addressing the inflammatory and immune-modulating aspects of cancer progression. Here, SELP is linked to cancer.